---
title: Standardized and quality-assured predictive PD-L1 testing in the upper gastrointestinal
  tract
date: '2023-10-24'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/37874352/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20231024180945&v=2.17.9.post6+86293ac
source: heidelberg[Affiliation]
description: As a result of the high approval dynamics and the growing number of immuno-oncological
  concepts, the complexity of treatment decisions and control in the area of cancers
  of the esophagus, gastroesophageal junction and stomach is constantly increasing.
  Since the treatment indication for PD-1 inhibitors that are currently approved in
  the European Union is often linked to the expression of PD-L1 (programmed cell death-ligand
  1), the evaluation of tissue-based predictive markers by the ...
disable_comments: true
---
As a result of the high approval dynamics and the growing number of immuno-oncological concepts, the complexity of treatment decisions and control in the area of cancers of the esophagus, gastroesophageal junction and stomach is constantly increasing. Since the treatment indication for PD-1 inhibitors that are currently approved in the European Union is often linked to the expression of PD-L1 (programmed cell death-ligand 1), the evaluation of tissue-based predictive markers by the ...